BR0207510A - Conjugados de peg de hgf-nk4 - Google Patents

Conjugados de peg de hgf-nk4

Info

Publication number
BR0207510A
BR0207510A BR0207510-5A BR0207510A BR0207510A BR 0207510 A BR0207510 A BR 0207510A BR 0207510 A BR0207510 A BR 0207510A BR 0207510 A BR0207510 A BR 0207510A
Authority
BR
Brazil
Prior art keywords
hgf
peg conjugates
kda
conjugate
chain
Prior art date
Application number
BR0207510-5A
Other languages
English (en)
Inventor
Michael Brandt
Apollon Papadimitriou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0207510A publication Critical patent/BR0207510A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"CONJUGADOS DE PEG DE HGF-NK4". A presente invenção refere-se a um conjugado compreendendo um fragmento de terminação N de fator de crescimento de hepatócito (HGF/SF) consistindo no domínio de forma de grampo e nas quatro regiões de kringle da cadeia a e um grupo polietileno glicol tendo um peso molecular total de aproximadamente 20 a 40 kDA, que tem propriedades melhoradas e é um agente terapêutico útil para tratamento de tumor.
BR0207510-5A 2001-02-23 2002-02-21 Conjugados de peg de hgf-nk4 BR0207510A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01104640A EP1234583A1 (en) 2001-02-23 2001-02-23 PEG-conjugates of HGF-NK4
PCT/EP2002/001837 WO2002074344A2 (en) 2001-02-23 2002-02-21 Peg-conjugates of hgt-nk4

Publications (1)

Publication Number Publication Date
BR0207510A true BR0207510A (pt) 2004-07-27

Family

ID=8176596

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207510-5A BR0207510A (pt) 2001-02-23 2002-02-21 Conjugados de peg de hgf-nk4

Country Status (27)

Country Link
US (2) US20030012775A1 (pt)
EP (2) EP1234583A1 (pt)
JP (2) JP2004521139A (pt)
KR (2) KR20030072629A (pt)
CN (1) CN100339393C (pt)
AR (1) AR032574A1 (pt)
AU (1) AU2002233354B2 (pt)
BG (1) BG108125A (pt)
BR (1) BR0207510A (pt)
CA (1) CA2438308A1 (pt)
CZ (1) CZ20032511A3 (pt)
EC (1) ECSP034741A (pt)
GT (1) GT200200038A (pt)
HR (1) HRP20030659A2 (pt)
HU (1) HUP0400979A2 (pt)
IL (1) IL157426A0 (pt)
MA (1) MA26998A1 (pt)
MX (1) MXPA03007130A (pt)
NO (1) NO20033737L (pt)
PA (1) PA8540501A1 (pt)
PE (1) PE20020992A1 (pt)
PL (1) PL367402A1 (pt)
RU (1) RU2293574C2 (pt)
SK (1) SK11652003A3 (pt)
WO (1) WO2002074344A2 (pt)
YU (1) YU65103A (pt)
ZA (1) ZA200306080B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019991A2 (en) * 2002-08-30 2004-03-11 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
WO2004085471A2 (en) * 2003-03-24 2004-10-07 Novo Nordisk A/S Glp-2 derivatives
EP1723236A1 (en) * 2004-03-03 2006-11-22 F.Hoffmann-La Roche Ag Method for the recombinant expression of an n-terminal fragment of hepatocyte growth factor
WO2005095449A1 (en) * 2004-03-03 2005-10-13 F. Hoffmann-La Roche Ag Method for the purification of an n-terminal fragment of hepatocyte growth factor
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
BRPI0911511B8 (pt) * 2008-04-09 2021-05-25 Helixmith Co Ltd formulação de dna liofilizadas para aumentar a expressão de dna de plasmídeo
CN102399293B (zh) * 2008-06-03 2013-12-04 中国科学院遗传与发育生物学研究所 一种与纤维蛋白特异结合的重组蛋白及其应用
US10532020B2 (en) 2012-08-22 2020-01-14 Revlon Consumer Products Corporation Nail coatings having enhanced adhesion
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
AU2014281828B2 (en) 2013-06-17 2019-05-09 Armo Biosciences, Inc. Method for assessing protein identity and stability
WO2015031316A1 (en) 2013-08-30 2015-03-05 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US11413332B2 (en) 2013-11-11 2022-08-16 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
CN107001438A (zh) 2014-10-14 2017-08-01 阿尔莫生物科技股份有限公司 白细胞介素‑15组合物及其用途
KR20170084033A (ko) 2014-10-22 2017-07-19 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위해 인터루킨-10을 사용하는 방법
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers
US20220118050A1 (en) * 2019-01-28 2022-04-21 Toray Industries, Inc. Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof
US20220220176A1 (en) * 2019-01-28 2022-07-14 Toray Industries, Inc. Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07508420A (ja) 1992-05-18 1995-09-21 ジェネンテク，インコーポレイテッド 肝細胞成長因子変異体
US6472178B1 (en) 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
GEP20002180B (en) * 1994-03-31 2000-07-25 Amgen Inc Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996028475A1 (fr) * 1995-03-10 1996-09-19 Nakamura, Toshikazu Facteur de croissance des hepatocytes modifie a l'aide de polyethylene glycol
EP0741187A2 (en) * 1995-05-05 1996-11-06 F. Hoffmann-La Roche Ag Recombinant obese (Ob) proteins
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
DK1007082T3 (da) 1997-01-15 2007-02-19 Phoenix Pharmacologics Inc Modificeret tumor nekrose faktor
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
EP0922446A1 (en) * 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
JP4574007B2 (ja) * 1998-04-28 2010-11-04 メルク・セローノ・ソシエテ・アノニム ポリオール−ｉｆｎ−ベータ複体
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
KR100645843B1 (ko) * 2000-12-20 2006-11-14 에프. 호프만-라 로슈 아게 에리트로포이에틴 접합체

Also Published As

Publication number Publication date
HRP20030659A2 (en) 2004-08-31
US7846896B2 (en) 2010-12-07
JP2004521139A (ja) 2004-07-15
NO20033737L (no) 2003-10-21
WO2002074344A3 (en) 2003-12-04
SK11652003A3 (sk) 2004-05-04
ECSP034741A (es) 2003-10-28
NO20033737D0 (no) 2003-08-22
KR20090020713A (ko) 2009-02-26
AR032574A1 (es) 2003-11-12
MXPA03007130A (es) 2003-11-18
BG108125A (bg) 2004-09-30
IL157426A0 (en) 2004-03-28
CN1571679A (zh) 2005-01-26
YU65103A (sh) 2006-03-03
EP1234583A1 (en) 2002-08-28
JP2010174034A (ja) 2010-08-12
PA8540501A1 (es) 2002-09-30
US20080085857A1 (en) 2008-04-10
EP1389132A2 (en) 2004-02-18
RU2293574C2 (ru) 2007-02-20
CN100339393C (zh) 2007-09-26
WO2002074344A2 (en) 2002-09-26
CZ20032511A3 (en) 2004-03-17
PE20020992A1 (es) 2002-11-01
HUP0400979A2 (hu) 2004-08-30
RU2003127395A (ru) 2005-03-20
US20030012775A1 (en) 2003-01-16
ZA200306080B (en) 2004-11-23
PL367402A1 (en) 2005-02-21
KR20030072629A (ko) 2003-09-15
CA2438308A1 (en) 2002-09-26
MA26998A1 (fr) 2004-12-20
GT200200038A (es) 2002-09-30
AU2002233354B2 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
BR0207510A (pt) Conjugados de peg de hgf-nk4
BR0210056A (pt) composições e métodos para tratamento de hiperplasia
UY27468A1 (es) Productos en gel para la axila, con componente de bloqueo de agua
CY1116023T1 (el) Μορφες φαρμακευτικης δοσολογιας παρατεταμενης απελευθερωσης με περιγραμματα διαλυτοποιησης ελαχιστοποιημενης εξαρτησης απο το ph
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BRPI0412671A (pt) conjugados de um polìmero e uma proteìna ligados por um grupo de ligação de oxima
ATE541587T1 (de) Konjugat-additionsreaktionen zur kontrollierten abgabe von pharmazeutisch wirksamen substanzen
BR0100046A (pt) Copolìmeros reticulados solúveis em água ou intumescìveis em água
BRPI0410503B8 (pt) composição tópica e uso da composição
BR0109272A (pt) Agentes conjugados terapêuticos de ácido poliglutâmico, métodos para suas preparações e usos
DE60004172D1 (de) Gcsf konjugate
DE60006100D1 (de) Lang wirkende insulinotrope peptide
BR0109931A (pt) Composições farmacêuticas
BR0115531A (pt) Tratamento de mucosites
BRPI0414017A8 (pt) pró-fármacos poliméricos de múltiplos braços
NO20026255L (no) Polymere micellesammensetninger
NO20014662D0 (no) Fremgangsmåter og preparater for behandling av faste tumorer
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
BR0210568A (pt) Conjugado, uso de um conjugado, composição farmacêutica, e, método para tratar câncer em um mamìfero
MXPA04004026A (es) Conjugados polimericos de inhibidores de la proteina quinasa c.
BRPI0414428A (pt) composições farmacêuticas
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
BR112023018842A2 (pt) Liberação de fármaco seletiva de conjugados
BR0207978A (pt) N-but-3enil norbuprenorfina e métodos de uso
BR0200246A (pt) Tratamento de combinação para a depressão

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. 61K 47/48, A61P 35/00

Ipc: A61K 47/48 (2011.01), A61P 35/00 (2011.01)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 10A. ANUIDADE(S),

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.

B15K Others concerning applications: alteration of classification

Ipc: A61K 47/60 (2017.01), A61P 35/00 (2006.01)